article thumbnail

Common pharma compliance concerns cited by FDA warning letters

European Pharmaceutical Review

A study of the causes of warning letters issued by the US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Health (CDRH) between 2010 and 2020 revealed that poor current good manufacturing practice (cGMP) compliance and misbranding were the most common citations.

FDA 89
article thumbnail

An Annex 1 and Pharma 4.0 perspective on water quality

European Pharmaceutical Review

1 The last four are produced at separate plants and thus less discussed for pharma since they are unlikely to be producing them in house. In particular, purified water and WFI are critical when producing sterile pharmaceutical drug products. Water quality from an Annex 1 and Pharma 4.0 John Wiley & Sons, Ltd, 2010.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharmaceutical Patents: A Challenge for Malaysia

Contrarian Sales Techniques

There was an article that examine the market for generic medicines in the Malaysia, following the introduction of the first generic patent in 2010 and the introduction of generic patent law in 2012. There are some countries in the world that do not require waiting for patent expiration to produce a generic version of a drug.

article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

SUMMARY: (JAMA) The median drug wholesale list price (as defined by Average Wholesale Price) increased by 129% from 2010-2016, while median patient out-of-pocket costs increased by 53% and median insurance payments after rebates and discounts increased by 64%. The Pharma Spin. Say goodbye to all the supposed goodwill.

Insurance 181